THMO - ThermoGenesis Holdings
Posizioni nette corte: Maire in vetta ai pi shortati di Piazza Affari, nelle prime posizioni anche Fincantieri e Webuild
Dall?ultimo aggiornamento disponibile di Consob sulle posizioni nette corte (PNC) si apprende che il titolo pi shortato a Piazza Affari Maire Tecnimontcon 4 posizioni short aperte per una quota pari al 4,63% del capitale sociale.Bio-On conquista il secondo gradino pi alto del podio con 2 PNC pari al 2,59% del capitale.Fincantieri si posiziona al
Settembre da incubo per Wall Street: occhio ad alcuni indicatori che lanciano dei segnali d’acquisto
Indici azionari di Wall Street in profondo rosso a settembre. Quando manca una seduta al termine del mese e del trimestre lo S&P 500 e gli altri principali indici viaggiano sui minimi annui. L?indice S&P 500 capitolato del 7,9% a settembre, il Dow Jones ha sofferto un tonfo del 7,2% e peggio fa il
Porsche in Borsa vale pi del doppio di Ferrari. Confronto con le altre big auto e prospettive dopo l’IPO pi attesa del 2022
Porsche si quotata sulla Borsa di Francoforte con il ticker P911 in quella che era l?Ipo pi attesa dell?anno e non ha deluso le aspettative. Si tratta infatti della maggiore IPO dell?ultimo decennio in Europa. Il debutto avvenuto in una giornata debole per i mercati, ma Porsche dopo aver aperto a 84 euro,
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #1

  2. #2

    Data Registrazione
    Apr 2020
    Messaggi
    235
    Mentioned
    0 Post(s)
    Quoted
    109 Post(s)
    Potenza rep
    0
    mi pare che sia l'ex CESCA , solo per precisare

  3. #3
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694
    Citazione Originariamente Scritto da toptrader88 Visualizza Messaggio
    mi pare che sia l'ex CESCA , solo per precisare
    che ticket aveva ?

  4. #4

    Data Registrazione
    Apr 2020
    Messaggi
    235
    Mentioned
    0 Post(s)
    Quoted
    109 Post(s)
    Potenza rep
    0
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    che ticket aveva ?
    KOOL

    Cesca Therapeutics To Change Name And Ticker Symbol To Reflect New Strategic Focus

  5. #5
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694

  6. #6
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694

    Premarket

    nel pre sta facendo +10%, in assenza di news ma, se non sbaglio anche gioved scorso ha fatto la stessa cosa chiudendo poi con un modesto +3,45%,
    vediamo oggi che fa

  7. #7
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694
    in realt ora una notizia uscita: ThermoGenesis Announces Its ImmuneCyte Joint Venture Acquires Key Technologies to Develop Fully Human Polyclonal and Monoclonal Antibody Therapeutics for COVID-19

    RANCHO CORDOVA, Calif., April 13, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that its joint venture, ImmuneCyte Life Sciences, Inc., has completed the acquisition of worldwide intellectual property for developing fully human antibody therapeutics for COVID-19. The acquired intellectual property includes four high-affinity monoclonal antibody drug candidates against SARS-CoV-2 (the virus causing COVID-19) and tools for screening and quantifying efficacy of such neutralizing antibodies. These high-affinity neutralizing monoclonal antibodies were obtained from the screening of enriched B cell libraries from individuals who have recently recovered from COVID-19 (i.e. from convalescent whole blood). The technologies were originally developed by a research team affiliated with East China Normal University, one of the most prestigious universities in China. The acquisition includes an undisclosed upfront cash payment and low double-digit future revenue sharing for the monoclonal antibody drug candidates under development. ThermoGenesis currently holds approximately 19% of the equity of ImmuneCyte.

    There are currently no regulatory approved vaccine or drug therapies for COVID-19. Current estimates are that a vaccine for emergency use may be available by early 2021. Convalescent plasma therapy is an exploratory approach that involves giving patients an infusion of plasma from people who have recovered from COVID-19. ThermoGenesis is developing a convalescent plasma strategy for COVID-19 with its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit, which, together with ImmuneCyte's newly acquired technologies, can quickly identify individuals who have developed protective immunity against the virus, and then, using ThermoGenesis' proprietary cell processing platform, allows for the simultaneous isolation of convalescent plasma and immune cells for potential anti-COVID-19 antibody development.

    The key effectors in convalescent plasma are neutralizing antibodies, which can block the entrance of the virus into the cells, thus achieving its anti-viral effects. Purified neutralizing polyclonal and monoclonal antibodies could be safer and more potent and are expected to have much higher efficacy than convalescent plasma. With the acquisition of these key intellectual property technologies, ImmuneCyte will be further engaged in the development of anti- COVID-19 polyclonal and monoclonal neutralizing antibodies for COVID-19 treatment.

    "The technologies acquired from a team associated with the world's leading institute in biological research will allow us to spearhead our antibody drug development against COVID-19," Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis, commented, "Given the gravity of the situation, both ThermoGenesis and ImmuneCyte are rapidly mobilizing our respective expertise and resources to fight against the pandemic. The acquisition of the new technologies by ImmuneCyte, along with ThermoGenesis' established proprietary technologies in the automated cellular processing field, will allow us to develop highly efficient processing methods for making convalescent plasma and pursue the development of fully human polyclonal and monoclonal antibody therapies against COVID-19."

  8. #8
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694

    Non scherzava stamattina...

    Clicca l'immagine per ingrandirla. 

Nome: THMO.jpg 
Visualizzazioni: 16 
Dimensione: 90.3 KB 
ID: 2679330

    buoni anche i volumi

  9. #9
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694
    nervosetta stasera, chiss se domani esce qualche notizia, spero positiva....

  10. #10
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,987
    Mentioned
    10 Post(s)
    Quoted
    1774 Post(s)
    Potenza rep
    42949694
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    nervosetta stasera, chiss se domani esce qualche notizia, spero positiva....
    molto nervose anche oggi....

Accedi